Jeff Zablocki

2.0k total citations
37 papers, 1.5k citations indexed

About

Jeff Zablocki is a scholar working on Molecular Biology, Physiology and Organic Chemistry. According to data from OpenAlex, Jeff Zablocki has authored 37 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 18 papers in Physiology and 12 papers in Organic Chemistry. Recurrent topics in Jeff Zablocki's work include Adenosine and Purinergic Signaling (18 papers), Synthesis and Biological Evaluation (10 papers) and Receptor Mechanisms and Signaling (8 papers). Jeff Zablocki is often cited by papers focused on Adenosine and Purinergic Signaling (18 papers), Synthesis and Biological Evaluation (10 papers) and Receptor Mechanisms and Signaling (8 papers). Jeff Zablocki collaborates with scholars based in United States, Australia and Belarus. Jeff Zablocki's co-authors include Elfatih Elzein, Rao Kalla, Kwan Leung, Luiz Belardinelli, Venkata P. Palle, Dewan Zeng, Thao Perry, John C. Shryock, William F. Kiesman and Brent Blackburn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nature Medicine.

In The Last Decade

Jeff Zablocki

37 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeff Zablocki United States 25 775 517 305 292 231 37 1.5k
Margot W. Beukers Netherlands 27 1.0k 1.3× 849 1.6× 410 1.3× 77 0.3× 418 1.8× 42 1.9k
Noel J. Cusack United Kingdom 29 833 1.1× 1.3k 2.5× 238 0.8× 350 1.2× 234 1.0× 61 2.2k
Jutta Hegler Germany 9 742 1.0× 371 0.7× 153 0.5× 63 0.2× 211 0.9× 10 1.1k
Silvia Paoletta United States 23 1.1k 1.4× 775 1.5× 357 1.2× 111 0.4× 440 1.9× 42 1.6k
Xiao‐duo Ji United States 26 1.1k 1.4× 1.3k 2.6× 688 2.3× 66 0.2× 329 1.4× 37 2.0k
James A. Bristol United States 18 816 1.1× 503 1.0× 668 2.2× 189 0.6× 240 1.0× 43 1.6k
Roger J. Hill United States 20 720 0.9× 130 0.3× 118 0.4× 227 0.8× 219 0.9× 30 1.2k
Bryan F. Cox United States 27 1.0k 1.3× 68 0.1× 96 0.3× 702 2.4× 316 1.4× 85 1.8k
Philip J. M. van Galen United States 16 610 0.8× 723 1.4× 400 1.3× 29 0.1× 187 0.8× 21 1.1k
Catherine Dacquet France 18 925 1.2× 67 0.1× 101 0.3× 90 0.3× 332 1.4× 49 1.5k

Countries citing papers authored by Jeff Zablocki

Since Specialization
Citations

This map shows the geographic impact of Jeff Zablocki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Zablocki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Zablocki more than expected).

Fields of papers citing papers by Jeff Zablocki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Zablocki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Zablocki. The network helps show where Jeff Zablocki may publish in the future.

Co-authorship network of co-authors of Jeff Zablocki

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Zablocki. A scholar is included among the top collaborators of Jeff Zablocki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Zablocki. Jeff Zablocki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Koltun, Dmitry O., Rao Kalla, Thao Perry, et al.. (2017). Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII). Bioorganic & Medicinal Chemistry Letters. 28(3). 541–546. 5 indexed citations
2.
Koltun, Dmitry O., Elfatih Elzein, Tetsuya Kobayashi, et al.. (2016). Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine. Bioorganic & Medicinal Chemistry Letters. 26(13). 3207–3211. 27 indexed citations
3.
Walker, James R., Paul Novick, William H. Parsons, et al.. (2012). Marked difference in saxitoxin and tetrodotoxin affinity for the human nociceptive voltage-gated sodium channel (Na v 1.7). Proceedings of the National Academy of Sciences. 109(44). 18102–18107. 82 indexed citations
4.
Yao, Lina, Peidong Fan, María Pía Arolfo, et al.. (2010). Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use–dependent inhibitor of dopamine synthesis. Nature Medicine. 16(9). 1024–1028. 80 indexed citations
5.
Arolfo, María Pía, David H. Overstreet, Lina Yao, et al.. (2009). Suppression of Heavy Drinking and Alcohol Seeking by a Selective ALDH‐2 Inhibitor. Alcoholism Clinical and Experimental Research. 33(11). 1935–1944. 78 indexed citations
6.
Koltun, Dmitry O., Vasily A. Migulin, Malcolm J. McGregor, et al.. (2009). Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(15). 4070–4074. 23 indexed citations
7.
Kiesman, William F., Elfatih Elzein, & Jeff Zablocki. (2009). A1 Adenosine Receptor Antagonists, Agonists, and Allosteric Enhancers. Handbook of experimental pharmacology. 25–58. 77 indexed citations
8.
Kalla, Rao, Jeff Zablocki, Mojgan Aghazadeh Tabrizi, & Pier Giovanni Baraldi. (2009). Recent Developments in A2B Adenosine Receptor Ligands. Handbook of experimental pharmacology. 99–122. 23 indexed citations
9.
Elzein, Elfatih & Jeff Zablocki. (2008). A1adenosine receptor agonists and their potential therapeutic applications. Expert Opinion on Investigational Drugs. 17(12). 1901–1910. 73 indexed citations
10.
Kalla, Rao, Elfatih Elzein, Thao Perry, et al.. (2008). Selective, high affinity A2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines. Bioorganic & Medicinal Chemistry Letters. 18(4). 1397–1401. 33 indexed citations
11.
Yang, Ming, Sandriyana Soelaiman, Rao Kalla, et al.. (2007). Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn-Schmiedeberg s Archives of Pharmacology. 375(2). 133–144. 70 indexed citations
12.
Elzein, Elfatih, Rao Kalla, Xiaofen Li, et al.. (2006). N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists. Bioorganic & Medicinal Chemistry Letters. 17(1). 161–166. 24 indexed citations
13.
Elzein, Elfatih, Rao Kalla, Xiaofen Li, et al.. (2005). Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 16(2). 302–306. 37 indexed citations
14.
Elzein, Elfatih, Kevin D. Shenk, Prabha N. Ibrahim, et al.. (2004). Novel inhibitors of fatty acid oxidation as potential metabolic modulators. Bioorganic & Medicinal Chemistry Letters. 14(4). 973–977. 6 indexed citations
15.
Zablocki, Jeff, Lin Wu, John C. Shryock, & Luiz Belardinelli. (2004). Partial A1 Adenosine Receptor Agonists from a Molecular Perspective and Their Potential Use as Chronic Ventricular Rate Control Agents During Atrial Fibrillation (AF). Current Topics in Medicinal Chemistry. 4(8). 839–854. 25 indexed citations
16.
Zablocki, Jeff, Rao Kalla, Thao Perry, et al.. (2004). The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma. Bioorganic & Medicinal Chemistry Letters. 15(3). 609–612. 56 indexed citations
17.
18.
Palle, Venkata P., Elfatih Elzein, Scott A. Gothe, et al.. (2002). Structure–affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor. Bioorganic & Medicinal Chemistry Letters. 12(20). 2935–2939. 25 indexed citations
19.
Gao, Zhenhai, Zhihe Li, Stephen P. Baker, et al.. (2001). Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists. Journal of Pharmacology and Experimental Therapeutics. 298(1). 209–218. 108 indexed citations
20.
Zablocki, Jeff, Venkata P. Palle, Elfatih Elzein, et al.. (2001). 2-SUBSTITUTED PI SYSTEM DERIVATIVES OF ADENOSINE THAT ARE CORONARY VASODILATORS ACTING VIA THE A2AADENOSINE RECEPTOR. Nucleosides Nucleotides & Nucleic Acids. 20(4-7). 343–360. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margot W. Beukers Breakdown of academic impact, for papers by Noel J. Cusack Breakdown of academic impact, for papers by Jutta Hegler Breakdown of academic impact, for papers by Silvia Paoletta Breakdown of academic impact, for papers by Xiao‐duo Ji Breakdown of academic impact, for papers by James A. Bristol Breakdown of academic impact, for papers by Roger J. Hill Breakdown of academic impact, for papers by Bryan F. Cox Breakdown of academic impact, for papers by Philip J. M. van Galen Breakdown of academic impact, for papers by Catherine Dacquet
Rankless by CCL
2026